During the past decade, Facharztzentrum Eppendorf conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 5 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Facharztzentrum Eppendorf" #1 sponsor was "Pfizer" with 3 trials, followed by "AIO-Studien-gGmbH" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "Sumitomo Pharma Oncology, Inc." with 2 trials sponsored and "EsoCap AG" with 2 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Facharztzentrum Eppendorf" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 3 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "Ono Pharmaceutical Co. Ltd" with 2 trials as a collaborator, "FGK Clinical Research GmbH" with 1 trials as a collaborator and "FGK Representative Service B.V." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Facharztzentrum Eppendorf" are "Eosinophilic Esophagitis" (3 trials), "Metastatic Colorectal Cancer" (2 trials), "Adenocarcinoma" (1 trials), "BRAF V600E-mutant Metastatic Colorectal Cancer" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Facharztzentrum Eppendorf" in a lesser frequency.

Most popular intervention types in "Facharztzentrum Eppendorf" are "Drug" (15 trials), "Other" (5 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Leucovorin" (4 trials), "Bevacizumab" (3 trials), "Cetuximab" (3 trials) and "Encorafenib" (3 trials). Other intervention names were less common.

The vast majority of trials in "Facharztzentrum Eppendorf" are 15 trials for "All" genders.

Currently, there are NaN active trials in "Facharztzentrum Eppendorf". undefined are not yet recruiting, 5 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 6 completed trials in Facharztzentrum Eppendorf, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Facharztzentrum Eppendorf, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".

Facharztzentrum Eppendorf has several departments that took part in Clinical trials: "Onkologische Schwerpunktpraxis Eppendorf" - 13 trials, "Facharztzentrum Eppendorf, Studien GbR" - 6 trials